
    
      The aim of this study is to evaluate the humoral response after vaccination against
      SARS-CoV-2 in a French multicenter cohort of patients with hemopathies. Analysis of
      hemopathies and immunochemotherapy subgroups will determine whether there is a need to
      strengthen immunization schedules. In addition, the study wish to assess the safety and
      clinical efficacy of mRNA vaccines in this cohort.
    
  